Hi M. I think there has been plenty published on the preclinical...

Hi M. I think there has been plenty published on the preclinical development of PBT2, although I did not see anything specific on the long term toxicity test that crushed the the value of the company. Or rather the reaction of the FDA to that test. 

The recent presentation on PBT434 was pretty specific and with great results like that why would they keep quiet.

"Results: At 11 and 16 months, PBT434 reduced alpha-synuclein aggregation (P=0.025 and 0.005, respectively) and preserved SN neurons (P=0.086 and 0.001, respectively). At 16 months, PBT434 reduced the number of GCI in SN and pons (P=0.0007 and 0.001, respectively). PBT434 improved motor function on the pole test at 16 months (P=0.049).Conclusions: PBT434 reduced alpha-synuclein aggregation and glial cell inclusions, preserved SN neurons and improved motor function in an animal model of MSA. PBT434 is a small molecule iron chaperone with potential for treating MSA.Share"